These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 31900915)

  • 1. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
    Yan Y; Huang H
    Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
    Mediwala SN; Sun H; Szafran AT; Hartig SM; Sonpavde G; Hayes TG; Thiagarajan P; Mancini MA; Marcelli M
    Prostate; 2013 Feb; 73(3):267-77. PubMed ID: 22821817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
    Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
    J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
    Lee SH; Johnson D; Luong R; Sun Z
    J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.
    Wang Y; Kreisberg JI; Ghosh PM
    Curr Cancer Drug Targets; 2007 Sep; 7(6):591-604. PubMed ID: 17896924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
    Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
    EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
    Sharma M; Chuang WW; Sun Z
    J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese medicinal compound CFF-1 induces the apoptosis and cycle-arrest of prostate cancer cells via the PI3K/AKT/FOXO1 signaling pathway].
    Zhang Y; Wu ZM; Lei BH; Lu ZJ; Zhu QY; Xu FS; Zhang MS; Liu P
    Zhonghua Nan Ke Xue; 2017 Sep; 23(9):828-837. PubMed ID: 29726666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.
    Hu Y; Sun H; Owens RT; Wu J; Chen YQ; Berquin IM; Perry D; O'Flaherty JT; Edwards IJ
    Neoplasia; 2009 Oct; 11(10):1042-53. PubMed ID: 19794963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.